This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
Get Sweet Surprise on Earnings From 5 Top-Ranked Stocks
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next releases.
Can PBM Unit Boost Express Scripts' (ESRX) Q2 Earnings?
by Zacks Equity Research
Strong performance by the PBM unit is likely to drive Express Scripts' (ESRX) top line in Q2. Home-delivery pharmacy care, specialty pharmacy care and drug data analysis services buoy optimism.
Will Global Industrial Unit Boost Ecolab's (ECL) Q2 Earnings?
by Zacks Equity Research
Solid performance in the Global Industrial segment is likely to drive Ecolab's (ECL) Q2 results. However, the company faces pricing pressure in the Energy segment.
Can Diagnostic Revenues Drive PerkinElmer (PKI) Q2 Earnings?
by Zacks Equity Research
Strong performance in the Diagnostics Segment is likely to drive PerkinElmer's (PKI) Q2 results. The segment fortifies the company's market position in terms of exclusiveness of services.
Merit Medical (MMSI) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Merit Medical's (MMSI) acquisition-driven strategy to boost growth by expanding existing product offerings across all business segments in Q2.
Is Bio-Rad Laboratories (BIO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BIO) Outperforming Other Medical Stocks This Year?
AngioDynamics (ANGO) Misses Q4 Earnings & Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) misses Q4 earnings and revenue estimates; international sales high.
Varian Medical (VAR) Q3 Earnings: Surprise in Store?
by Zacks Equity Research
Solid prospects in the Oncology segment is likely to boost Varian Medical's (VAR) top-line performance in the third quarter of fiscal 2018.
Will Core Distribution Unit Aid McKesson (MCK) Q1 Earnings?
by Zacks Equity Research
Strong prospects in the Distribution Solutions segment is likely to boost McKesson's (MCK) top-line performance in the fiscal first quarter.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
We are upbeat about Bio-Rad's (BIO) solid growth in geographies like North America, China and Asia Pacific.
Here's Why You Should Invest in Baxter (BAX) Stock Right Now
by Zacks Equity Research
Baxter's (BAX) raised 2018 guidance and strong international presence make it a lucrative pick.
Bio-Rad (BIO) Up 13.5% in 3 Weeks Post Solid Q1 Earnings
by Zacks Equity Research
Bio-Rad (BIO) Q1 results reflect impressive segmental sales and solid performance across all geographies.
3 Reasons Why You Should Invest in Baxter International Now
by Zacks Equity Research
Baxter (BAX) gains ground on strategic buyouts and a raised guidance for 2018.
Integra LifeSciences (IART) Tops on Q1 Earnings, '18 View Up
by Zacks Equity Research
Integra LifeSciences' (IART) revenue growth was primarily driven by high organic revenues, successful progress with Codman integration and progress with the channel expansion strategy.
LabCorp (LH) Beats on Q1 Earnings, Revenues, Lifts '18 View
by Zacks Equity Research
LabCorp's (LH) Diagnostics business was solid on the back of increasing acquisitions, organic volume expansion and a favorable foreign exchange scenario.
Illumina (ILMN) Beats on Q1 Earnings, Lifts '18 Guidance
by Zacks Equity Research
Illumina's (ILMN) collaboration with Bristol-Myers Squibb and Loxo Oncology are likely to yield results in the near term.
Here's Why You Should Invest in Integer Holdings Right Now
by Zacks Equity Research
Integer Holdings' (ITGR) unswerving focus on customer relationship, cost reduction and burgeoning financial performance are key catalysts.
Edwards Lifesciences' (EW) THVT Likely to Drive Q1 Earnings
by Zacks Equity Research
Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies in Q1.
Here's Why You Should Invest in Stryker (SYK) Right Now
by Zacks Equity Research
Stryker (SYK) gains from stellar performance of the flagship Mako platform; guidance solid.
Chemed (CHE) Beats on Q1 Earnings & Revenues, Retains View
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q1.
Quest Diagnostics (DGX) Q1 Earnings Meet, Guidance Intact
by Zacks Equity Research
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q1 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained
by Zacks Equity Research
Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.
Intuitive Surgical (ISRG) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical's (ISRG) da Vinci platform drives growth in Q1, international sales rise.
Here's Why You Should Hold on to Cerner (CERN) Stock for Now
by Zacks Equity Research
Cerner (CERN) gains ground on solid EHR platform, stiff competition raises concern.
Can MedSurg Business Aid Boston Scientific (BSX) Q1 Earnings?
by Zacks Equity Research
Boston Scientific's (BSX) MedSurg business is likely to deliver an encouraging show in Q1 on the back of a strong endoscopy, driven by biliary, hemostasis, EndoChoice and Symetis buyouts.